GSA Capital Partners’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

GSA Capital Partners’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-324,784	Closed	-$386K	–	2010
2022 Q3	$386K	Buy	+324,784	New	+$350K	0.05%	769
2022 Q2	–	Sell	-279,605	Closed	-$319K	–	1921
2022 Q1	$319K	Buy	+279,605	New	+$334K	0.04%	853
2021 Q4	–	Sell	-89,878	Closed	-$307K	–	1910
2021 Q3	$307K	Sell	89,878 -127,809	-59%	-$394K	0.03%	1001
2021 Q2	$651K	Buy	+217,687	New	+$689K	0.07%	464
2018 Q4	–	Sell	-284,354	Closed	-$771K	–	1844
2018 Q3	$771K	Sell	284,354 -5,500	-2%	-$11.4K	0.04%	840
2018 Q2	$554K	Sell	289,854 -12,300	-4%	-$24.9K	0.03%	1106
2018 Q1	$635K	Buy	302,154 +288,500	+2,113%	+$618K	0.03%	948
2017 Q4	$28K	Buy	+13,654	New	+$28.3K	﹤0.01%	1514
2015 Q2	–	Sell	-19,446	Closed	-$272K	–	2240
2015 Q1	$272K	Buy	+19,446	New	+$297K	0.01%	1767

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

GSA Capital Partners's INFI Position: Q4 2022 in Review

GSA Capital Partners sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2022, closing a stake of 324,784 shares — an estimated $386K sold.

GSA Capital Partners first reported a position in INFI in Q1 2015 and held it in 9 quarters. The position peaked at $771K in Q3 2018. 68 funds tracked by Wall St. Rank hold INFI as of Q4 2022.

GSA Capital Partners reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 324,784 Infinity Pharmaceuticals, Inc. shares in Q4 2022, an estimated $386K.
GSA Capital Partners first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2015 and held it in 9 quarters.
GSA Capital Partners's Infinity Pharmaceuticals, Inc. position peaked at $771K in Q3 2018.
68 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.